Reply to Assoc. Prof. Kocak

Authors

  • Linda Willén Center for Research and Development, Uppsala University/Region Gävleborg, Gävle, Sweden; Department of Radiation Sciences and Oncology, Umeå University, Umeå, Sweden; Department of Oncology, Gävle Hospital, Gävle, Sweden
  • Anders Berglund EpiStat, Uppsala, Sweden
  • Stefan Bergström Center for Research and Development, Uppsala University/Region Gävleborg, Gävle, Sweden; Department of Radiation Sciences and Oncology, Umeå University, Umeå, Sweden; Department of Oncology, Gävle Hospital, Gävle, Sweden
  • Johan Isaksson Center for Research and Development, Uppsala University/Region Gävleborg, Gävle, Sweden; Department of Pulmonary Medicine, Gävle Hospital, Gävle, Sweden; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
  • Michael Bergqvist Department of Radiation Sciences and Oncology, Umeå University, Umeå, Sweden
  • Gunnar Wagenius Division of Oncology, Department of Clinical Science Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
  • Mats Lambe Regional Cancer Center Central Sweden, Uppsala, Sweden

DOI:

https://doi.org/10.1080/0284186X.2021.2023216

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2022-03-04

How to Cite

Willén, L., Berglund, A., Bergström, S., Isaksson, J., Bergqvist, M., Wagenius, G., & Lambe, M. (2022). Reply to Assoc. Prof. Kocak. Acta Oncologica, 61(3), 320. https://doi.org/10.1080/0284186X.2021.2023216

Issue

Vol. 61 No. 3 (2022): Acta Oncologica

Section

Articles